Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Rad, Inpeco Building Interfaces for Clinical Dx

NEW YORK (GenomeWeb News) – Bio-Rad Laboratories and Inpeco today announced a deal to build interfaces between Bio-Rad's clinical diagnostics platforms and Inpeco's FlexLab system.

The deal covers Bio-Rad's systems for diabetes, autoimmune disease, and infectious disease testing, and aims to provide clinical diagnostics labs "a complete and integrated solution that automates sample processing, consolidates testing platforms, and improves operating efficiency of the instruments," the partners said in a statement.

The first interfaces will be built for Bio-Rad's Variant II Turbo hemoglobin testing system and BioPlex 2200 system. Variant II Turbo uses HPLC to measure hemoglobin A1C, which is used to monitor average blood glucose levels over time in diabetic patients. BioPlex 2200 is Bio-Rad's multiplex system for the testing of autoimmune and infectious diseases.

Inpeco is based in Lugano, Switzerland. Its FlexLab is an open automation system for handling samples and standardizing sample processing, among other things.

Financial and other terms of the deal were not disclosed.